Tirzepatide (LY3298176) in Patients With Type 2 Diabetes (SURPASS-3)

In by ECIR

Tirzepatide (LY3298176) in Patients With Type 2 Diabetes (SURPASS-3)

  • This field is for validation purposes and should be left unchanged.

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of Tirzepatide Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes



Inclusion Criteria

• Diagnosed with type 2 diabetes mellitus (T2DM)
• HbA1c between ≥7.0% and ≤10.5%
• Current treatment includes metformin or metformin plus an SGLT-2 inhibitor

Exclusion Criteria

• Type 1 diabetes mellitus
• History of chronic or acute pancreatitis
• Proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment
• Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
• Have an estimated glomerular filtration rate <45 mL/minute/1.73 m2 • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2

Back to Current Studies